Natera Signatera

Natera has launched Signatera, a research-use-only circulating tumor DNA assay. Signatera consists of analyzing whole-exome sequencing data from a patient's tumor sample to design a targeted, custom-designed assay to analyze 16 or more mutations that were identified in the tumor sample. According to Natera, the assay can detect variant allele frequencies down to 0.01 percent and is optimized to achieve high specificity by requiring detection of multiple mutations for a ctDNA-positive call, leading to fewer false positives.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.